Targeting the inflammatory response in secondary stroke prevention: A role for combining aspirin and extended-release dipyridamole

American Journal of Therapeutics

Volumn 16, Issue 2, 2009, Pages 164-170

  Weyrich, Andrew S ^a   Skalabrin, Elaine J ^a   Kraiss, Larry W ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Antiplatelet; Dipyridamole; Ischemic stroke; Secondary stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE;

ARTICLE; BLEEDING; DIARRHEA; DISEASE CONTROL; DIZZINESS; DRUG ACTIVITY; DRUG TARGETING; DYSPEPSIA; HEADACHE; HUMAN; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; PROPHYLAXIS; STOMACH PAIN; STROKE; TREATMENT OUTCOME; VOMITING;

ASPIRIN; CLINICAL TRIALS AS TOPIC; DIPYRIDAMOLE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; INFLAMMATION; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; STROKE;

EID: 64649096165     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31814b17bf     Document Type: Article

References (30)

1. Sacco RL, Adams R, Albers G, et al. American Heart Association; American Stroke Association Council on Stroke; Council on Cardiovascular Radiology and Intervention; American Academy of Neurology. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37:577-617.
2. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005;4:977-987.
3. Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke. 2001;32:280-299.
4. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
5. Awtry EH, LoscaLzo J. Aspirin. In: Michelson AD, ed. Platelets, 1st ed. San Diego: Academic Press; 2002: 803-815.
6. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1-13.
7. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
8. De Schryver E, Algra A, van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev. 2006;19: CD001820.
9. Derendorf H, VanderMaelen CP, Brickl R, et al. Dipyridamole bioavailability in subjects with reduced gastric acidity. J Clin Pharmacol. 2005;45:845-850.
10. The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomized controlled trial. Lancet. 2006; 367:1665-1674.
11. Lindgren A, Husted S, Staaf G, et al. Dipyridamole and headache-a pilot study of initial dose titration. J Neurol Sci. 2004;223:179-184.
12. Theis JG, Deichsel G, Marshall S. Rapid development of tolerance to dipyridamole-associated headaches. Br J Clin Pharmacol. 1999;48:750-755.
13. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-126.
14. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111:3481-3488.
15. Glagov S, Weisenberg E, Zarins CK, et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316:1371-1375.
16. Ikonomidis I, Andreotti F, Economou E, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 1999; 100:793-798.
17. Offner H, Subramanian S, Parker SM, et al. Experimental stroke induces massive, rapid activation of the peripheral immune system. / Cereb Blood Flow Metab. 2006;26: 654-665.
18. Rallidis LS, Vikelis M, Panagiotakos DB, et al. Inflammatory markers and in-hospital mortality in acute ischaemic stroke. Atherosclerosis. 2006;189:193-197.
19. Woodward M, Lowe GD, Campbell DJ, et al. Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke. 2005;36:2143-2147.
20. Eisert WG. Dipyridamole. In: Michelson AD, ed. Platelets, 1st ed. San Diego: Academic Press; 2002:803-815.
21. Khan Q, Mehta JL. Relevance of platelet-independent effects of aspirin to its salutary effect in atherosclerosis-related events. J Atheroscler Thromb. 2005;12:185-190.
22. Wollner A, Wollner S, Smith JB. Acting via A2 receptors, adenosine inhibits the upregulation of Mac-1 (Cdllb/CD18) expression on FMLP-stimulated neutrophils. Am J Respir Cell Mol Biol. 1993;9:179-185.
23. Chello M, Mastroroberto P, Malta E, et al. Inhibition by dipyridamole of neutrophil adhesion to vascular endothelium during coronary bypass surgery. Ann Thorac Surg. 1999;67:1277-1282.
24. Weyrich AS, Denis MM, Kuhlmann-Eyre JR, et al. Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates. Circulation. 2005;111:633-642.
25. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res. 2004;95:858-866.
26. Verhoeven B, Hellings WE, Moll FL, et al. Carotid atherosclerotic plaques in patients with transient ischemic attacks and stroke have unstable characteristics compared with plaques in asymptomatic and amaurosis 0fugax patients. J Vase Surg. 2005;42:1075-1081.
27. Zhao L, Gray L, Leonardi-Bee J, et al. Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke. Platelets. 2006;17:100-104.
28. Rogowski O, Shapira I, Assayag EB, et al. Lack of significant effect of low doses of aspirin on the concentrations of C-reactive protein in a group of individuals with atherothrombotic risk factors and vascular events. Blood Coagul Fibrinolysis. 2006;17:19-22.
29. Feldman M, Jialal I, Devaraj S, et al. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay, J Am Coll Cardiol. 2001; 37:2036-2041.
30. Diener HC, Sacco R, Yusuf S. Steering Committee and PRoFESS Study Group. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively avoiding Second Strokes (PRoFESS) Trial. Cerebrovasc Dis. 2007;23:368-380.